King Rachel K.

Director at NVAX; President, CEO at CBIO

Sold, on record
$367k
Dollars the filings state
Form 4 sales
2
Latest Dec 13, 2024
Form 144 notices
1
Proposed sales
Companies
2
Filed as an executive or holder

Companies

  • NVAXNOVAVAX INCDirector
  • CBIOCRESCENT BIOPHARMA, INC.President, CEO

Sales by reason

0
Routine
0
Plan not stated
0
No plan
0
Unusual
Stacked: routine sales under a plan, sales whose filing does not state a plan, sales with no plan, and unusual sales.

Form 4 sales per month, last 12 months.

Sales chart range

Sales by company

Shares sold, every Form 4 sale on record.

Timeline

  1. 1 Form 4 sale CBIOPlan not stated
    Dec 28, 2020 2020

    Sold 84,176 shares at $3.91 ($329k)

    King Rachel K., President, CEO

    Sold 19.1% of holdings ($1.7M position)356,064 shares leftFirst sale on recordFiling

  2. 2 Form 144 notice NVAXNotice
    Dec 13, 2024 +1446 days

    Filed to sell 4,150 shares ($37k)

    King Rachel K., Board Member

    No 10b5-1 planFirst sale on recordFiling

  3. 3 Form 4 sale NVAXNo plan
    Dec 13, 2024 same day

    Sold 4,150 shares at $9.02 ($37k)

    King Rachel K., Director

    No 10b5-1 planSold 21.9% of holdings ($171k position)14,770 shares leftFirst sale on recordFollows a Form 144Filing

Every transaction

Loading transactions…

Sales and notices (3)

Form 144 notices and Form 4 sales by King Rachel K.
Source
Dec 13, 2024Jan 2, 2025NVAXDirectorForm 4 sale4,150$37k21.9%No planSEC
Dec 13, 2024Dec 13, 2024NVAXBoard MemberForm 144 notice4,150$37kNoticeSEC
Dec 28, 2020Dec 30, 2020CBIOPresident, CEOForm 4 sale84,176$329k19.1%Plan not statedSEC